1-Cells from rodents and humans express different receptors recognizing hormones of the secretin-glucagon family, which--when activated--synergize with glucose in the control of insulin release. We have recently reported that isolated islets from mice homozygous for a GLP-1 receptor null mutation (GLP-1R(-/-)) exhibit a well-preserved insulin-secretory response to glucose. This observation can be interpreted in two different ways: 1) the presence of GLP-1R is not essential for the secretory response of isolated islets to glucose alone; 2) beta-cells in GLP-1R(-/-) pancreases underwent compensatory changes in response to the null mutation. To explore these possibilities, we studied islets from control GLP-IR(+/+) mice in the absence or presence of 1 pmol/l exendin (9-39)amide, a specific and potent GLP-1R antagonist. Exendin (9-39)amide (15-min exposure) reduced glucose-induced insulin secretion from both perifused and statically incubated GLP-1R(+/+) islets by 50% (P < 0.05), and reduced islet cAMP production in parallel (P < 0.001). Furthermore, GLP-1R(-/-) islets exhibited: 1) reduced cAMP accumulation in the presence of 20 mmol/l glucose (knockout islets versus control islets, 12 +/- 1 vs. 27 +/- 3 fmol x islet(-1) x 15 min(-1); P < 0.001) and exaggerated acceleration of cAMP production by 10 nmol/l glucose-dependent insulinotropic peptide (GIP) (increase over 20 mmol/l glucose by GIP in knockout islets versus control islets: 66 +/- 5 vs. 14 +/- 3 fmol x islet(-1) x 15 min(-1); P < 0.001); 2) increased mean cytosolic [Ca2+] ([Ca2+]c) at 7, 10, and 15 mmol/l glucose in knockout islets versus control islets; and 3) signs of asynchrony of [Ca2+]c oscillations between different islet subregions. In conclusion, disruption of GLP-1R signaling is associated with reduced basal but enhanced GIP-stimulated cAMP production and abnormalities in basal and glucose-stimulated [Ca2+]c. These abnormalities suggest that GLP-1R signaling is an essential upstream component of multiple beta-cell signaling pathways.
Skip Nav Destination
Article navigation
Abstract|
October 01 1999
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.
D Flamez;
D Flamez
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
P Gilon;
P Gilon
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
K Moens;
K Moens
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
A Van Breusegem;
A Van Breusegem
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
D Delmeire;
D Delmeire
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
L A Scrocchi;
L A Scrocchi
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
J C Henquin;
J C Henquin
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
D J Drucker;
D J Drucker
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
F Schuit
F Schuit
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Search for other works by this author on:
Citation
D Flamez, P Gilon, K Moens, A Van Breusegem, D Delmeire, L A Scrocchi, J C Henquin, D J Drucker, F Schuit; Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.. Diabetes 1 October 1999; 48 (10): 1979–1986. https://doi.org/10.2337/diabetes.48.10.1979
Download citation file: